The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial
Open accessAbstract
Background In preclinical studies, davunetide promoted microtubule stability and reduced tau phosphorylation. Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP. We assessed the safety and efficacy of davunetide in patients with PSP.Methods In a double-blind, parallel group, phase 2/3 trial, participants were randomly assigned with permuted blocks in a 1:1 ratio to davunetide (30 mg twice daily, intranasally) or placebo for 52 weeks at 48 centres in Australia, Canada, France, Germany, the UK, and the USA. Participants met the modified Neuroprotection and Natural History in Parkinson Plus Syndrome study criteria for PSP. Primary endpoints were the change from baseline in PSP Rating Scale (PSPRS) and Schwab and England Activities of Daily Living (SEADL) scale at up to 52 weeks. All participants and study personnel were masked to treatment assignment. Analysis was by intention to treat. The trial is registered with Clinicaltrials.gov, number NCT01110720.Findings 313 participants were randomly assigned to davunetide (n=157) or to placebo (n=156), and 241 (77%) completed the study (118 and 156 in the davunetide and placebo groups, respectively). There were no differences in the davunetide and placebo groups in the baseline PSPRS and SEADL. The davunetide and placebo groups did not differ in the change from baseline in PSPRS (median 11·8 [95% CI 10·5 to 13·0] vs 11·8 [10·5 to 13·0], respectively, p=0·41) or SEADL (-0·20 [-0·20 to -0·17] vs -0·20 [-0·22 to -0·17], respectively, p=0·92). 54 serious adverse events were reported in each of the treatment groups, including 11 deaths in the davunetide group and ten in the placebo group. The frequency of nasal adverse events was greater in the davunetide group than in the placebo group (epistaxis 18 [12%] of 156 vs 13 [8%] of 156, rhinorrhoea 15 [10%] vs eight [5%], and nasal discomfort 15 [10%] vs one [<1%]).Interpretation Davunetide is not an effective treatment for PSP. Clinical trials of disease-modifying treatment are feasible in patients with PSP and should be pursued with other promising tau-directed treatments.Funding Allon Therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the latest phase II/III study162, patients with PSP were treated with NAP for 52 weeks, but no differences were found between placebo-treated and NAP-treated patients163.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [163]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519
Self-citationProgressive Supranuclear Palsy
Steele, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,930
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges
Williams, D. R., & Lees, A. J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70042-0 · Cited by 650
Self-citationSchneider, L., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, ., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 646
Self-citationA clinical rating scale for progressive supranuclear palsy
Golbe, L. I., & Ohman‐Strickland, P. (2007) · Brain · doi:10.1093/brain/awm032 · Cited by 628
Self-citationIdentification of common variants influencing risk of the tauopathy progressive supranuclear palsy
PSP Genetics Study Group, Höglinger, G. U., Melhem, N. M., Dickson, D. W., Sleiman, P. M. A., Wang, L.-S., Klei, L., Rademakers, R., de Silva, R., Litvan, I., et al. (2011) · Nature Genetics · doi:10.1038/ng.859 · Cited by 603
Self-citationHall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473
Neuropathology of variants of progressive supranuclear palsy
Dickson, D. W., Ahmed, Z., Algom, A. A., Tsuboi, Y., & Josephs, K. A. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833be924 · Cited by 386
Cited by
Sorted by citations
Items 201–294 of 294
Bluett, B., & Litvan, I. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1018180 · Cited by 8
Self-citationKovács, G. G., Respondek, G., van Eimeren, T., Holler, E., Levin, J., Müller, U., Schwarz, S. C., Rösler, T. W., Schweyer, K., & Höglinger, G. U. (2018) · Der Nervenarzt · doi:10.1007/s00115-018-0584-3 · Cited by 8
Self-citationAre PSP patients included in clinical trials representative of the general PSP population?
Mariani, L., Guimarães‐Costa, R., Grabli, D., Toullec, B. L., Cormier‐Dequaire, F., Degos, B., Dubois, B., Vidailhet, M., Lacomblez, L., & Corvol, J. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.07.012 · Cited by 8
Self-citationDisease‐Modifying Treatments for Progressive Supranuclear Palsy
Stamelou, M., & Boxer, A. L. (2015) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12142 · Cited by 9
Self-citationGozes, I., Ivashko‐Pachima, Y., Kapitansky, O., Sayas, C. L., & Iram, T. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2019.05.014 · Cited by 8
Self-citationInvestigational therapeutics for the treatment of progressive supranuclear palsy
Coughlin, D. G., & Litvan, I. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2087179 · Cited by 8
Self-citationPatients with progressive supranuclear palsy need to be seen sooner and more frequently
Dale, M. L., Ali, F., Anderson, S., Bruno, M. K., Comeau, M., Diaz, K., Golbe, L. I., Honig, L. S., Schmidt, M., Spears, C. C., et al. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105883 · Cited by 7
Self-citationThe tauopathies: Neuroimaging characteristics and emerging experimental therapies
Riley, K. J., Graner, B. D., & Veronesi, M. C. (2022) · Journal of Neuroimaging · doi:10.1111/jon.13001 · Cited by 8
Neuroprotective Drug Development: The Story of ADNP, NAP (Davunetide), and SKIP
Gozes, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00013-2 · Cited by 7
Self-citationBrain Networks Route Neurodegeneration Patterns in Patients with Progressive Supranuclear Palsy
Palleis, C., Quattrone, A., Dehsarvi, A., Roemer, S. N., Bernhardt, A. M., The AL‐108‐231 Investigators, T. P. S. G., Huppertz, H., Malpetti, M., Boxer, A. L., Gnörich, J. S., et al. (2025) · Movement Disorders · doi:10.1002/mds.30257 · Cited by 6
Self-citationBrain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy
Quattrone, A., Franzmeier, N., Huppertz, H., Seneca, N. M., Petzold, G. C., Spottke, A. E., Levin, J., Prudlo, J., Düzel, E., the PASSPORT Study Group, T. A. I., et al. (2025) · Movement Disorders · doi:10.1002/mds.70026 · Cited by 6
Self-citationPainous, C., Fernández, M., Cámara, A., Albà-Arbalat, S., Soto, M., Brenlla, C., Muñoz, E., Pérez‐Soriano, A., Valldeoriola, F., Martı́, M. J., et al. (2025) · Movement Disorders · doi:10.1002/mds.70086 · Cited by 6
Emerging drugs for progressive supranuclear palsy
Giagkou, N., & Stamelou, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1609450 · Cited by 6
Ali, F., & Josephs, K. A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678584 · Cited by 5
Microtubule stabilising peptides: new paradigm towards management of neuronal disorders
Bhargava, S., Kulkarni, R., Dewangan, B., Kulkarni, N., Jiaswar, C., Kumar, K., Kumar, A., Bodhe, P. R., Kumar, H., & Sahu, B. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00012e · Cited by 5
Grey-matter correlates of empathy in 4-Repeat Tauopathies
Tafuri, B., Urso, D., Nigro, S. L., Macchitella, L., Blasi, R. D., Chaudhuri, К. R., & Logroscino, G. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00576-z · Cited by 5
Efficiency of multivariate tests in trials in progressive supranuclear palsy
Yousefi, E., Gewily, M., König, F., Höglinger, G. U., Hopfner, F., Karlsson, M. O., Ristl, R., Zehetmayer, S., & Posch, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-76668-4 · Cited by 5
Self-citationProgressive supranuclear palsy treatment—A systematic review
Hajjar, S. H., & Cooper, J. K. (2016) · Basal Ganglia · doi:10.1016/j.baga.2016.01.004 · Cited by 5
Storey, K., Johanidesová, S., Matěj, R., Keller, J., Rohan, Z., & Rusina, R. (2016) · Neurocase · doi:10.1080/13554794.2016.1264058 · Cited by 5
Therapeutic options for Progressive Supranuclear Palsy including investigational drugs
Shoeibi, A., & Litvan, I. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1335596 · Cited by 5
Self-citationCordero, I. R. G., Vargas‐González, J., Hadian, M., Bayram, E., Rodriguez‐Porcel, F. E., Couto, B., Iyer, J. M., Golbe, L. I., Stephen, C. D., Pantelyat, A. Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70485 · Cited by 4
Self-citationTau and Alzheimer’s Disease: Molecular Mechanisms and Treatment Approaches
Reiss, A. B., Muhieddine, D., Leon, A. Z. D., Voloshyna, I., Gomolin, I. H., & Pinkhasov, A. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-021-01092-y · Cited by 4
Progressive Supranuclear Palsy
Agarwal, S., & Gilbert, R. (2019) · StatPearls · Cited by 4
Molecular profiling in Parkinsonian syndromes: CSF biomarkers
Paoletti, F. P., Gaetani, L., & Parnetti, L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.002 · Cited by 5
Dam, T., Yang, L., Gillis, C., Li, Y., O'Gorman, J. T., Kolb, B., Boxer, A. L., Golbe, L. I., Haeberlein, S. B., & On behalf of the AL-108-231, P. (2025) · Nature Communications · doi:10.1038/s41467-024-55442-0 · Cited by 3
Self-citationZhu, R., Kim, G., Rajewski, B. H., Angera, I. J., Valle, J. R. D., & Wang, Y. (2025) · Advanced NanoBiomed Research · doi:10.1002/anbr.202500065 · Cited by 3
Pérez‐Soriano, A., Painous, C., Fernandez, M., Perez-Montesino, J., de Mena, L., Zaro, I., Cámara, A., & Compta, Y. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03070-3 · Cited by 4
Clinical Trial Development in Frontotemporal Lobar Degeneration
Ljubenkov, P. A., & Boxer, A. L. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.019 · Cited by 3
Self-citationConcomitant Medications for Progressive Supranuclear Palsy
Iyer, J. M., Gunzler, D. D., Lang, A. E., Golbe, L. I., Pantelyat, A. Y., Boxer, A. L., Wills, A.-M. A., & AL-108-231 Study Group (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5215 · Cited by 3
Self-citationMolecular Pathways in Alzheimer’s Disease and Cognitive Function
Chen, X., Reichert, M. C., & Gan, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802851-3.00005-x · Cited by 3
A new step towards targeting tau
Corvol, J., & Buée, L. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30161-9 · Cited by 3
Self-citationNatural Plant Materials as a Source of Neuroprotective Peptides
Skibska, A., & Perlikowska, R. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230703145043 · Cited by 3
Xie, T., Liao, C., & Golbe, L. I. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13906 · Cited by 3
Self-citationImmunotherapeutics for AD: A Work in Progress
Sharma, A., Anand, J. S., & Kumar, Y. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210903101522 · Cited by 3
Gozes, I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00001-x · Cited by 3
Self-citationProgressive Supranuclear Palsy and Corticobasal Syndrome
McFarland, N. R. (2025) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001607 · Cited by 2
Exploration of the Medicinal Peptide Space
Gevaert, B., Stalmans, S., Wynendaele, E., Taevernier, L., Bracke, N., D’Hondt, M., & Spiegeleer, B. M. J. D. (2016) · Protein and Peptide Letters · doi:10.2174/0929866523666160215162326 · Cited by 2
Atypical parkinsonism, parkinsonism-plus syndromes and secondary parkinsonian disorders
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00009-3 · Cited by 2
The Differentiation of Progressive Supranuclear Palsy
Cordato, N. J., & Halliday, G. M. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.15.37 · Cited by 2
Chemical Modulators of Protein Misfolding, Neurodegeneration and Tau
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801944-3.00001-1 · Cited by 2
Frontotemporal lobar degeneration
Kim, B., Viera-Ortiz, A., Phan, J. M., Irwin, D. J., & Lee, E. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00041-1 · Cited by 3
Diagnoses of corticobasal syndrome and corticobasal degeneration
Shimohata, T., Aiba, I., & Nishizawa, M. (2016) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-000841 · Cited by 2
Luca, D. G. D., & Lang, A. E. (2021) · Brain · doi:10.1093/brain/awab115 · Cited by 2
Self-citationNeuroprotektive Therapien bei Tauopathien
Respondek, G., Krey, L., Huber, M. K., Pflugrad, H., Wegner, F., & Höglinger, G. U. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01210-0 · Cited by 3
Self-citationProgressive Supranuclear Palsy
Morris, H. R. (2017) · Neurodegeneration · doi:10.1002/9781118661895.ch8 · Cited by 2
Tau-Centric Therapies for Treating Alzheimer’s Disease
Quraishe, S., Cowan, C. M., & Mudher, A. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00005-3 · Cited by 1
Germani, M., Mesa, I. R., Buchanan, T. J., Bruyn, S. D., Gasalla, T., Tricht, H. L. G. V., Ewen, C., Golbe, L. I., Boxer, A. L., & Höglinger, G. U. (2024) · Movement Disorders · doi:10.1002/mds.30027 · Cited by 1
Self-citationLi, E., Song, F., Coppola, Q., Yack, L. M., Le, M. M., Javed, S., Pandher, N., Prufer, I., Mayzel, O., Heuer, H. W., et al. (2026) · Trials · doi:10.1186/s13063-025-09382-9 · Cited by 1
Self-citationTauopathies and its therapeutic interventions in Alzheimer’s disease
Sonawane, S. K., Rangappa, N., Chidambaram, H., & Chinnathambi, S. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2025.12.001 · Cited by 1
Neuroprotection trial design in progressive supranuclear palsy: challenges and solutions
Golbe, L. I., & Thomas, R. G. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70247 · Cited by 1
Self-citationShapira, G., Blatt, J., Guz, L. S., Shomron, N., & Gozes, I. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03709-x · Cited by 1
Self-citationWhen should neuroprotective drugs move from mice to men?
Tariot, P. N. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70112-7 · Cited by 1
Progressive supranuclear palsy
Федорова, Н. В., Витальевна, Б. Е., Kulua, T. K., & Mikhaylova, A. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2021121051111 · Cited by 1
Corticobasal Degeneration and Corticobasal Syndrome
Saranza, G., Armstrong, M. J., & Lang, A. E. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108989855.034 · Cited by 1
Self-citationScotton, W. J., Shand, C., Todd, E. G., Bocchetta, M., Kobylecki, C., Cash, D. M., VandeVrede, L. A., Heuer, H. W., Quaegebeur, A., Young, A. L., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf066 · Cited by 3
Self-citationLa paralysie supranucléaire progressive
Eusébio, A. (2015) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2015.01.006 · Cited by 1
Ernenwein, D., John, S. E. S., Stewart, A. J., Morimoto, B. H., Chmielewski, J. A., & Lipton, M. A. (2020) · Peptide Science · doi:10.1002/pep2.24179 · Cited by 1
Self-citationBroad kinase inhibition mitigates early neuronal dysfunction and cognitive deficits in tauopathyPreprint
Koren, S. A., Hamm, M. J., Cloyd, R., Fontaine, S. N., Chishti, E. A., Lanzillotta, C., Rodriguez-Rivera, J., Ingram, A., Bell, M. C., Escobar, S. M. G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.31.229583 · Cited by 1
Reply to: “Brief Clinical Rating Scales Should Not Be Overlooked”
Respondek, G., Piot, I., & Höglinger, G. U. (2020) · Movement Disorders · doi:10.1002/mds.28273 · Cited by 1
Self-citationGozes, I., Shapira, G., Lobyntseva, A., & Shomron, N. (2023) · Research Square · doi:10.21203/rs.3.rs-2457393/v1 · Cited by 1
Self-citationProgressive supranuclear palsy finally has a clinically measureable abnormality
Halliday, G. M. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308567
Tau Targeted but Trial Negative in Progressive Supranuclear Palsy
Matthews, B. R. (2014) · Journal watch · doi:10.1056/nejm-jw.na34839
Aktuelle Therapiestudien im Bereich der atypischen Parkinson Syndrome
Schweyer, K., Levin, J., & Höglinger, G. U. (2018) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-0586-3440
Self-citationThe postsynaptic protein neurogranin: a new item in the Alzheimer’s disease biomarker toolbox
Kvartsberg, H. (2019) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Störungen der Basalganglienfunktion
Franke, C., & Storch, A. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-21882-8.00008-6
Vogel, U. &. (2014) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-014-0977-1
Miller‐Patterson, C., Krobot, K. E., Burton, E. A., & Smith, L. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-28852-5_13
Progressive Supranuclear Palsy
Josephs, K. A. (2015) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0025798
Cartelli, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818000-6.00006-8
Reply to: “Application of the mPSPRS to the Salerno Cohort”
Respondek, G., & Höglinger, G. U. (2021) · Movement Disorders · doi:10.1002/mds.28754
Self-citationProgressive Supranuclear Palsy
Stamelou, M., & Oertel, W. H. (2017) · Springer eBooks · doi:10.1007/978-3-7091-1628-9_18
(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-21884-2.00033-7
Progressive Supranuclear Palsy
Cherchi, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-94841-1_94
Treatment of Frontotemporal Dementias
Chen, D., VandeVrede, L. A., & Boxer, A. L. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108985055.022
Self-citationThe core herpes simplex-1 fusion complex drives cell-to-cell spreading of pathological TauPreprint
Heumüller, S.-E., Sushkin, M. E., Sánchez-Sendín, E., Hossinger, A., Stappert, D., Altinisik, N., Seiwert, L., Paulsen, L., Krawczyk, A., Klupp, B. G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.21.700770
Castro, J. G., VandeVrede, L. A., Donohue, M., Vaqué‐Alcázar, L., Rubio‐Guerra, S., Selma‐González, J., Heuer, H. W., Morcillo-Nieto, A. O., Franquesa‐Mullerat, M., Dols‐Icardo, O., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100486
Self-citationCaractérisation d'anticorps à domaine unique dirigés contre la protéine Tau
Danis, C. (2018) · theses.fr (ABES) · doi:10.70675/c783a062zb57bz4024z85d0z509baaed8a1b
Siddique, I. A., Hong, M., & Bitan, G. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_189
Spatiotemporal Tau Accumulation and Its Clinical Impact on PSP: Longitudinal Florzolotau (18F) PETPreprint
Chishiki, Y., Tagai, K., Kataoka, Y., Goto, R., Osawa, K., Oyama, A., Matsumoto, H., Ichihashi, M., Momota, Y., Kamada, T., et al. (2026) · medRxiv · doi:10.64898/2026.04.26.26350467
A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders
Eijsvogel, P. P. N. M., Smits, L. M. G., Kremer, P. H. C., & Groeneveld, G. J. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70315 · Cited by 1
Wang, X., Liu, Z., & Smith, W. W. (2026) · Brain Sciences · doi:10.3390/brainsci16050525
Nose-to-Brain Delivery of Biologicals
Torres, J., Correia, A. C., & Silva, A. C. (2025) · Springer handbooks · doi:10.1007/978-3-032-01636-2_8
Chua, J. P., Toh, T. S., Lim, D. W. P., Lim, T. Q., Chen, K. K. N., Tee, Y. X., Lim, Y. Z., Fernandiz, J. C., Yap, K. H., Tay, Y. W., et al. (2026) · medRxiv · doi:10.64898/2026.07.23.26358755
Harris, G. A., Barnhard, L., Brummet, J., & Diaz, K. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1893149
Bang, K. Y., Walenga, R. L., Chopski, S. G., Luke, M. C., Blinova, K., Zhao, L., & Guo, S. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115938 · Cited by 1
Satlin, A., Cordingley, M. G., Liebert, D. K., Bee, W., Geier, E. G., Sedivy, J. M., Soto, J., Duan, J., Dickson, S. P., Chu, L., et al. (2026) · Movement Disorders · doi:10.1002/mds.70470
A Rare Case of Steel Richardson Syndrome: A Variant of Progressive Supranuclear Palsy
Reddy, C. S., & Harshitha, K. (2026) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.22.s5.24
Therapeutic targeting of tauopathies: From druggable biology to precision intervention
Zhang, C., Ma, J., Wu, X., Wang, X., Huang, X., Zheng, H., & Zhao, Y. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108432
Chishiki, Y., Tagai, K., Kataoka, Y., Goto, R., Osawa, K., Oyama, A., Matsumoto, H., Ichihashi, M., Momota, Y., Kamada, T., et al. (2026) · Movement Disorders · doi:10.1002/mds.70468
Synthetic Targeted Peptides in Therapy
Shiryaeva, O. S., Smirnov, E. A., Znamensky, V. A., Murashko, E. A., Kolobov, A. A., Бондаренко, А. Б., Korolev, D. V., Galagudza, M. M., & Cheburkin, Y. V. (2026) · Nanobiotechnology Reports · doi:10.1134/s2635167626602366
Targeting protein aggregate co-pathologies in neurodegeneration: a viable therapeutic strategy?
Buck, S. A., Madhavan, S. S., & Sanders, L. H. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00047-8
Siejka, T. P., Bertram, K., Butzkueven, H., Darby, D., & Brodtmann, A. G. (2026) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70847
Zdunek, J., & Grodner, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209094
Metadata
- Authors
- Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., Corvol, J.-C., Ludolph, A., Burn, D., Lorenzl, S., Litvan, I., Roberson, E. D., Höglinger, G. U., Koestler, M., Jack, C. R., Van Deerlin, V., Randolph, C., Lobach, I. V., Heuer, H. W., Gozes, I., Parker, L., Whitaker, S., Hirman, J., Stewart, A. J., Gold, M., & Morimoto, B. H.
- Affiliations
- University of California, San Francisco (US)
- University of Toronto (CA)
- University of Pennsylvania (US)
- Mayo Clinic (US)
- University of Southern California (US)
- Baylor College of Medicine (US)
- UCL Queen Square Institute of Neurology (GB)
- Rutgers, The State University of New Jersey (US)
- Monash University (AU)
- University Hospital Ulm (DE)
- Newcastle University (GB)
- LMU Klinikum (DE)
- University of California San Diego (US)
- University of Alabama at Birmingham (US)
- Technical University of Munich (DE)
- Loyola University Chicago (US)
- Tel Aviv University (IL)
- Arbutus Biopharma (Canada) (CA)
- Omeros Corporation (United States) (US)
- Paladin Labs (Canada) (CA)
- Celerion (United States) (US)
- Corresponding author
- Boxer, Adam L
- ORCID
- Boxer, Adam L
- Lang, Anthony E
- Grossman, Murray
- Knopman, David S
- Miller, Bruce L
- Schneider, Lon S
- Lees, Andrew
- Golbe, Lawrence I
- Williams, David R
- Burn, David
- Lorenzl, Stefan
- Litvan, Irene
- Roberson, Erik D
- Höglinger, Günter U
- Jack, Clifford R
- Randolph, Christopher
- Lobach, Iryna V
- Heuer, Hilary W
- Gozes, Illana
- Stewart, Alistair J
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 13
- Issue
- 7
- Pages
- 676-685
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC4129545
- OpenAlex
- W2129669150
- Cited by
- 294
- References
- 43
- Citations by year
- 2026: 21 · 2025: 18 · 2024: 15 · 2023: 22 · 2022: 16 · 2021: 25 · 2020: 27 · 2019: 33 · 2018: 23 · 2017: 27 · 2016: 36 · 2015: 20 · 2014: 10
- FWCI
- 20.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Allos Therapeutics
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- davunetide, progressive supranuclear palsy, tau pathology, microtubule stabilization, tau phosphorylation, intranasal drug delivery, neuroprotection, PSP Rating Scale, activities of daily living, drug safety, epistaxis, serious adverse events, atypical parkinsonism, disease-modifying therapy
- MeSH terms
- Aged, Double-Blind Method, Female, Humans, Male, Oligopeptides, Supranuclear Palsy, Progressive, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
